Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 189 trials in your specialties ()
View trials across your selected specialties

Screening Inhaled Allergen Challenge for Dermatophagoides Farinae

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Asthma
View Full Trial
INTERVENTION

Biological: Der f

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UNC Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States

Brief Summary

This study is designed to identify Dermatophagoides farinae, or Der f, sensitive asthmatics who demonstrate a late phase asthmatic response after Der f inhalation. These subjects may be invited to participate in a planned future study investigating novel asthma treatments.

Dobutamine on the Cardiac Conduction System

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Arrhythmias, Cardiac
View Full Trial
INTERVENTION

Drug: Dobutamine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Long Island Jewish Hospital, New Hyde Park, New York, United States

Brief Summary

Our hypothesis is that Dobutamine will act in a similar fashion to Isoproterenol with respect to cardiac conduction. Our goal is to study the effects of Dobutamine on cardiac conduction and refractoriness during an Electrophysiology study (EPS). At the end of most EPS Isoproterenol is commonly administered in an effort to change the conduction properties of the heart. In our practice we have been using Dobutamine for this purpose for many years. Dobutamine has never been rigorously studied for this indication however. We designed this study to systematically study the effect of various doses of Dobutamine on the parameters of cardiac conduction and refractoriness that are commonly measured during an EPS. We are specifically looking to compare the effect that Dobutamine has on the sinus node with the effect it has on the atrioventricular node. Patients undergoing an EPS at Long Island Jewish Hospital will be recruited and consented. Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Recurrent Head and Neck Carcinoma
View Full Trial
INTERVENTION

Radiation: Brachytherapy, Drug: Cesium-131, Procedure: Conventional surgery

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Brief Summary

This pilot clinical trial studies cesium Cs 131 brachytherapy in treating patients with head and neck cancer that has come back (recurrent) and can be removed by surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Radioactive drugs, such as cesium Cs 131, may carry radiation directly to tumor cells and not harm normal cells. Permanently implanting cesium Cs 131 into the wound bed after surgery may help treat microscopic cancer cells that may be in the tissue after surgical removal of the tumor.

Evaluating Neuromuscular Stimulation for Restoring Hand Movements

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Healthy Volunteers, Spinal Cord Injury Cervical, Physical and Reh...
View Full Trial
INTERVENTION

Device: Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Northwell Health's The Feinstein Institute for Medical Research, Manhasset, New York, United States

Brief Summary

The specific aim of this study is to evoke functional movement in the hand of both healthy individuals and individuals diagnosed with a stable cervical spinal cord injury with non-functional movement of the fingers. The primary purpose of this study is to determine the feasibility of achieving refined hand movements through electrical stimulation of the muscles within the forearm. It is believed that this study will be able to identify specific stimulation parameters and electrode spatial configurations responsible for various refined hand movements. After an eligible individual agrees to participate in this study, s/he will receive transcutaneous electrical stimulation on the forearm in order to evoke different hand and finger movements. The precision, specificity, and extent of these movements will be visually assessed. In order to better evaluate these movements, participants may also be asked to perform various functional tasks with their hand. The grip strength and evoked forces at the fingertips will also be measured using sensors. There will be up to 4 study sessions each week for up to 8 weeks, with each session lasting up to 4 hours. Upon completion of these study sessions, the individual's participation in the study is considered complete.

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Quizartinib, Healthy Subjects, Drug-drug Interaction, Pharmacokin...
View Full Trial
INTERVENTION

Drug: Dabigatran Etexilate Mesylate, Drug: Quizartinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Worldwide Clinical Trials, San Antonio, Texas, United States

Brief Summary

The purpose of this study is to investigate the one-way drug-drug interaction potential of quizartinib on dabigatran etexilate in healthy adult participants.

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
View Full Trial
INTERVENTION

Drug: Standard heparin dose, Drug: Real time heparin dose adjustment

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Utah, Salt Lake City, Utah, United States

Brief Summary

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

MRI and PET to Assess Pembrolizumab Response

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Malignant Melanoma, Metastatic
View Full Trial
INTERVENTION

Drug: Pembrolizumab, Drug: FLT PET

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Columbia University, New York, New York, United States

Brief Summary

The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving Pembrolizumab (MK-3475).

A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Healthy Adult Volunteers
View Full Trial
INTERVENTION

Drug: Activated charcoal

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Brief Summary

This is a pilot study designed to test feasibility, tolerability, and safety of medical grade oral Activated Charcoal (AC) in 12 healthy volunteers.

Modafinil and Cognitive Function in POTS

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Postural Tachycardia Syndrome
View Full Trial
INTERVENTION

Drug: Placebo, Drug: Modafinil, Drug: Propranolol

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Vanderbilt University, Nashville, Tennessee, United States

Brief Summary

A common complaint among patients with Postural Tachycardia Syndrome (POTS) is "brain fog" or difficulty concentrating. This problem is poorly understood. The purpose of this study is to better understand the cognitive dysfunction associated POTS, and to determine optimal treatment strategies for this condition. In this study, the investigators will test the hypothesis that acute administration of the psychostimulant drug modafinil can improve seated measures of cognitive function in patients with POTS.

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Spinal Cord Injuries, Neurogenic Bladder, Cognitive Change
View Full Trial
INTERVENTION

Drug: Mirabegron

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

South Texas Veterans Health Care System, Audie L. Murphy Hospital, San Antonio, Texas, United States

Brief Summary

We propose to test the hypothesis that cognition will improve with substitution of mirabegron for the anticholinergic agent (AC) in elderly persons with spinal cord injury (SCI) who require neurogenic bladder (NGB) treatment.